EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Karyopharm Therapeutics's enterprise value is $112.5 Mil.
Karyopharm Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-118.4 Mil. Therefore, Karyopharm Therapeutics's EV-to-EBITDA for today is -0.95.
The historical rank and industry rank for Karyopharm Therapeutics's EV-to-EBITDA or its related term are showing as below:
KPTI'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -32.35 Med: -3.54 Max: -0.16
Current: -0.95
During the past 13 years, the highest EV-to-EBITDA of Karyopharm Therapeutics was -0.16. The lowest was -32.35. And the median was -3.54.
KPTI's EV-to-EBITDA is ranked worse than 100% of 474
companies
in the Biotechnology industry
Industry Median: 9.165
vs KPTI: -0.95
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-24), Karyopharm Therapeutics's stock price is $1.09.
Karyopharm Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.250. Therefore, Karyopharm Therapeutics's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Karyopharm Therapeutics EV-to-EBITDA Historical Data
The historical data trend for Karyopharm Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Karyopharm Therapeutics's EV-to-EBITDA
For the Biotechnology subindustry, Karyopharm Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Karyopharm Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Karyopharm Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Karyopharm Therapeutics's EV-to-EBITDA falls into.
Karyopharm Therapeutics EV-to-EBITDA Calculation
Karyopharm Therapeutics's EV-to-EBITDA for today is calculated as:
Karyopharm Therapeutics's current Enterprise Value is $112.5 Mil.
Karyopharm Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-118.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Karyopharm Therapeutics's PE Ratio for today is calculated as:
Karyopharm Therapeutics's share price for today is $1.09.
Karyopharm Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.250.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Karyopharm Therapeutics EV-to-EBITDA Related Terms
Thank you for viewing the detailed overview of Karyopharm Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Karyopharm Therapeutics (Karyopharm Therapeutics) Business Description
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
KPTI has been successfully added to your 